Long noncoding RNAs (lncRNAs) play crucial roles in regulating chromatin dynamics and gene expression, and their dysregulation is closely linked to tumorigenesis. However, their specific functions in gastric cancer (GC) remain poorly understood. Here, we found that lncRNA solute carrier family 16 member 1 antisense RNA 1 (SLC16A1-AS1) was markedly overexpressed in GC through integrated RNA sequencing (RNA-seq) analysis and validation in clinical tissues. High SLC16A1-AS1 expression correlated with advanced cancer stage, greater invasion depth, and poorer patient prognosis. Functional assays showed that SLC16A1-AS1 overexpression promoted GC cell proliferation, whereas knockdown inhibited proliferation in vitro and in vivo. Mechanistically, SLC16A1-AS1 interacted with the 5-methylcytosine (m5C) methyltransferase NOL1/NOP2/ SUN (NSUN2), enhancing m5C modification of GRP78 mRNA, which stabilized the transcript and increased GRP78 protein levels. Rescue experiments demonstrated that GRP78 overexpression reversed the proliferation-inhibitory effect of SLC16A1-AS1 depletion. These findings reveal that SLC16A1-AS1 drives GC cell proliferation via NSUN2-mediated m5C modification of GRP78 mRNA, suggesting a potential target for GC diagnosis and therapy.

The immunosuppressive microenvironment of osteosarcoma (OS) and the inherent toxicity of current neoadjuvant chemotherapy present significant challenges in treatment, highlighting the urgent need for innovative therapeutic approaches. Photodynamic therapy (PDT) is a promising noninvasive alternative; however, its clinical application is limited by the poor stability of traditional photosensitizers (PS), insufficient reactive oxygen species (ROS) production, and a weak antitumor immune response. Given these limitations, a combination therapy that enhances PDT's therapeutic efficacy while stimulating immune activation could offer a more effective strategy. In this study, we developed a biomimetic nanomedicine (IR780@EM) by integrating the near-infrared photosensitizer IR780 with Escherichia coli-derived membrane nanovesicles (EM). This approach synergistically combines localized PDT with systemic antitumor immunity, leading to enhanced ROS generation and promoting M2-to-M1 polarization of macrophages in tumor, thereby activating the immune system and driving OS regression. Unlike conventional chemotherapy-based treatments, this strategy not only addresses the key limitations of PDT-insufficient ROS production and limited immune activation-but also helps overcome chemotherapy resistance and convert immunologically "cold" tumors into "hot" tumors, thereby improving therapeutic outcomes. This EM-based nanotherapeutic strategy holds significant translational potential for optimizing PDT efficacy and offers a multidimensional treatment approach for OS.

OBJECTIVE:To observe the efficacy and complications of one-stage tumor resection to treat primary sacral neurogenic tumors and to discuss some details in the clinically relevant anatomy.METHODS:A retrospective analysis of 26 patients with neurogenic turors of the sacral spine who were surgically treated from January 2001 to January 2018, including 16 males and 10 females, aged from 21 to 69 years old with an average age of (39.3±10.9) years old. The courses of diseases ranged from 3 to 56 months with an average of (17.9±10.1) months. The diameters of presacral components ranged from 3.3 to 19.6 cm with an average of (8.7±4.1) cm. The proximal margin of presacral lesions was above the L5S1 level in 6 cases, and lower than L5S1 in 20 cases. A posterior incision approach for one-stage complete resection of the tumor was used firstly, and an anterior approach was combined when necessary. Spinal-pelvic reconstruction with the modified Galveston technique was also carried out in relevant cases. Whether to preserve the tumor-involved nerve roots depended on the situation during the operation. The operation time, intraoperative blood loss, pain relief, and complications were recorded. The lumbosacral spine stability and sacral plexus neurological function were evaluated during postoperative follow-up, and local recurrence and distant metastasis were examined as well.RESULTS:Total excision was achieved in all 26 patients, with an operation time of (160.4±35.3) mins and an intraoperative blood loss of (1 092.3±568.8) ml. Tumors have been removed via a posterior-only approach in 21 cases and via combined anterior/posterior approaches in 5 cases. The diameter of presacral masses components ranged from 11.3 to 19.6 cm with an average of (15.1±3.2) cm in patients with combined anterior/posterior approaches, and ranged from 3.3 to 10.9 cm with an average of (7.2±2.4) cm in patients with a posterior-only approach. Five of the six patients whose proximal margin of presacral masses was above the L5S1 level adopted combined anterior/posterior approaches, and 20 patients lower than the L5S1 level adopted the posterior-only approach. All the patients were followed up for 6 to 82 months with an average of(45.4±18.2)months. Postoperative lumbosacral pain and lower extremity radicular pain were significantly relieved, and sensation, muscle strength and bowel and bladder function were also improved to varying degrees. The postoperative early complications included superficial wound infection in 1 case and cerebrospinal fluid leakage in 2 cases. Pathology confirmed 17 cases of schwannoma, 7 cases of neurofibroma and 2 cases of malignant schwannoma. Local recurrence was observed in two cases of benign neurogenic tumors. One patient with a malignant nerve sheath tumor had lung metastasis, who died 20 months after the operation. In 17 cases of upper sacral neurogenic tumors, 4 cases did not undergo spinal-pelvic reconstruction with internal fixation, of which 2 cases suffered from postoperative segmental instability. Tumor-involved nerve roots were resected during surgery in 7 cases. One of these patients who had S2 and S3 nerve roots sacrificed simultaneously had an impaired bladder and bowel function postoperatively, and did not recover completely. In the other 6 cases, the neurological function was not damaged obviously or recovered well.CONCLUSION:The posterior approach can directly expose the lesions, and it is also convenient to deal with nerve roots and blood vessels. The operation time, intraoperative blood loss, degree of symptom relief, complication rate, and recurrence and metastasis rate can be controlled at an appropriate level. It is a safe and effective surgical approach. When the upper edge of the presacral mass is higher than the L5S1 level or the diameter of the presacral mass exceeds 10 cm, an additional anterior approach should be considered. The stress between the spine and pelvis is high, and internal fixation should be used to restore the mechanical continuity of the spine and pelvis during resection of neurogenic tumors of the high sacral spine. Most of the parent nerve roots have lost their function. Resection of a single parent nerve root is unlikely to cause severe neurological dysfunction, while the adjacent nerve roots have compensatory functions and should be preserved as much as possible during surgery.

Abstract Trial design: This study prospectively analyzes the effect of EPO combined with Iron sucrose on postoperative anemia prevention and prognosis of patients with TKA. Methods: Participants in this study will be randomly assigned to a treatment group or control group. Patients in the treatment group will receive EPO for ten days combined with iron sucrose injection for three days preoperative. The general data, hematological indexes, transfusion rate, total blood loss, and knee joint function score will be analyzed. Results: 92 patients met the inclusion criteria, including 46 patients in the treatment group and 46 in the control group. There were no significant statistical differences in descriptive characteristics of the population between the two groups. The results indicated that the anemic rate of the treatment group was significantly lower than the control group after treatment (67.4%vs93.5%, P=0.001). The hematological index also has a significant difference in the two groups, such as Postoperative Hb, RBC count, Hct. The treatment group, perioperative blood loss, was significantly lower than the control group (587.69±340.81ml vs. 812.72±329.7ml, P=0.002). The treatment group showed a better HSS score and WOMAC score (HSS score: P=0.007; WOMAC score: P=0.001), HSS score improved 3.37 points, and WOMAC scores improved 12.08 points after the operation than the control group. No postoperative blood transfusion and postoperative complications occurred in the study period. Conclusions: According to our study, we found that perioperative treatment of erythrocyte mobilization in patients with TKA can improve postoperative hemoglobin level, reduce postoperative total blood loss, and reduce postoperative anemic rate without increased drug costs on the hospitalization expenses. Patients who receive erythrocyte mobilization treatment can significantly accelerate erythropoiesis after surgery and promote the hemoglobin level to normal more quickly. The patients after treatment show an advantage in HSS score and WOMAC score.

The aim of the present study was to analyze the expression of focal adhesion kinase (FAK) in osteosarcoma (OS) cell lines with different migration abilities in order to determine the role of FAK in migration. A number of different 143B subclone cell lines (A1, A2, A3, A4 and A5) were obtained by a limiting dilution method, and the expression of FAK was detected using western blot analysis. The role of FAK in the migration of OS cells was investigated using small interfering RNA (siRNA), and the ratio of the number of lamellipodia was compared by immunofluorescence staining. The A2 and A3 OS 143B subclone cell lines demonstrated a stronger migration ability and exhibited higher FAK expression compared with the A1 cell line (P<0.05). Following transfection with FAK-siRNA, the migration ability of the A3 cells was significantly decreased (P<0.05), and the ratio of the number of lamellipodia formed was reduced from 35 to 11% (P<0.05). In conclusion, the level of FAK expression was higher in the cell lines with a stronger migration ability. FAK affects the migration ability of OS cells by suppressing the formation of lamellipodia.

The authors have withdrawn this preprint due to erroneous posting.

Osteosarcoma (OS) is the most common highly malignant bone tumor in teens. Vasculogenic mimicry (VM) is defined as de novo extracellular matrix-rich vascular-like networks formed by highly aggressive tumor cells. We previously reported the presence of VM and it is an unfavorable prognostic factor in OS patients. Long noncoding RNAs (lncRNAs) are aberrantly expressed in OS and involved in cancer cell VM. However, lncRNAs in VM formation of OS have not been investigated. We, therefore, profiled the expression of lncRNAs in highly aggressive OS cell line 143B compared with its parental poorly aggressive cell line HOS. The differentially expressed (DE) lncRNAs and messenger RNA (mRNAs) were subjected to constructed lncRNA-mRNA coexpressed network. The top-ranked hub gene lncRNA n340532 knockdown 143B cells were used for in vitro and in vivo VM assays. The annotation of DE lncRNAs was performed according to the coexpressed mRNAs by Gene Ontology and pathway analysis. A total of 1360 DE lncRNAs and 1353 DE mRNAs were screened out. lncRNA MALAT1 and FTX, which have known functions related to VM formation and tumorigenesis were identified in our data. The coexpression network composed of 226 lncRNAs and 118 mRNAs in which lncRNA n340532 had the highest degree number. lncRNA n340532 knockdown reduced VM formation in vitro. The suppression of n340532 also exhibited potent anti-VM and antimetastasis effect in vivo, suggesting its potential role in OS VM and metastasis. Furthermore, n340532 coexpressed with 10 upregulation mRNAs and 3 downregulation mRNAs. The enriched transforming growth factor-β signaling pathway, angiogenesis and so forth were targeted by those coexpressed mRNAs, implying n340532 may facilitate VM formation in OS through these pathways and gene functions. Our findings provide evidence for the potential role of lncRNAs in VM formation of OS that could be used in the clinic for anti-VM therapy in OS.

目的 探讨重楼提取物(PPEE)抗骨肉瘤作用及其机制.方法 不同质量浓度的PPEE处理骨肉瘤细胞,采用MTT法、Hoechst 33342染色、流式细胞术、Matrigel培养、免疫印迹法分别检测细胞增殖抑制率、细胞凋亡、细胞周期、血管生成拟态(VM)形成及相关蛋白表达情况.裸鼠移植瘤模型观察PPEE的体内抑瘤效果.结果 PPEE对骨肉瘤细胞半数抑制浓度(IC50)为10～60 μg/mL,对成骨细胞增殖影响较小.PPEE可浓度依赖性地将骨肉瘤143B细胞阻滞在G2/M期,上调细胞周期相关蛋白p-CDK1、p-Cdc25C、p-Chk2表达,下调cyclin BI表达;促进细胞凋亡,上调cleaved Caspase-3、8、9和PARP表达,上调Bax/Bcl-2;抑制细胞体外VM形成,下调FAK、Mig-7、MMP-2和MMP-9表达.体内实验显示PPEE能明显抑制骨肉瘤生长和体内VM形成,延长荷瘤裸鼠生存期.结论 PPEE在体内外均具有良好的抗骨肉瘤活性,其作用机制可能与诱导骨肉瘤细胞凋亡、阻滞细胞周期及破坏骨肉瘤VM形成有关.

Vasculogenic mimicry (VM) is a special type of vascular channel formed by tumor cells without endothelial cell participation. Migration-inducing gene 7 (MIG-7) plays an important role in regulating VM. In this study, immunohistochemical staining was used to detect MIG-7 in tissue specimens from 141 primary osteosarcoma patients, and the relationship between MIG-7 and VM was examined. Survival analysis were performed to evaluate the prognoses. MIG-7 knockdown osteosarcoma cells were used for cell proliferation, apoptosis, migration, invasiveness and VM formation assays. A spontaneously metastasizing cell line-derived orthotopic xenograft mouse model was established to evaluate the effect of MIG-7 knockdown on tumorigenesis, VM formation and lung metastasis. MIG-7 expression was associated with VM formation. There were significant differences in overall and metastasis-free survival between the MIG-7-positive and MIG-7-negative groups. The MIG-7 expression was shown to be an independent indicator of both overall and metastasis-free survival. In vitro knockdown of MIG-7 dramatically reduced migration, invasion and VM formation in osteosarcoma cells without any significant effect on cell proliferation and apoptosis. MIG-7 knockdown also exhibited potent antitumor, antimetastasis and anti-VM effects in the orthotopic mouse model of 143B osteosarcoma. Therefore, MIG-7 serves as an independent unfavorable prognostic indicator in osteosarcoma patients and MIG-7 is an important mediator of osteosarcoma VM formation.

Paris polyphylla, a traditional antipyretic-detoxicate chinese medicinal herb, has been applied extensively in cancer treatments for nearly 2000 years. The purpose of the present study is to evaluate the potential anti-osteosarcoma effects of Paris polyphylla ethanol extract (PPEE) and to investigate its underlying mechanisms. The antiproliferation activity of PPEE was tested on 143B, MG-63, U-2 OS and hFOB1.19 cells using MTT assay. The pro-apoptotic and cell cycle arrest effects of PPEE were confirmed by Hoechst 33342 staining and flow cytometry. The antimigratory, anti-invasive and antivasculogenic mimicry (VM) effects of PPEE were investigated by wound healing, Transwell and 3D culture assays. Mouse xenograft model was used to examine its anti-osteosarcoma efficacy in vivo. Hematologic profiles and hepatorenal functions were evaluated to assess the toxicity of PPEE. PPEE evidently suppressed cell proliferation of 143B, MG-63 and U-2 OS with IC50 values of 10-60[Formula: see text][Formula: see text]g/mL, but showed little cytotoxicity against normal osteoblastic cell. PPEE promoted apoptosis in 143B cell via caspase activation, increased Bax/Bcl-2 ratio and PARP cleavage. It also induced G2/M phase arrest associated with elevated phosphorylation of CDK1, Cdc25C, Chk2 and down-regulation of cyclin B1, CDK1, Cdc25C expression. Additionally, PPEE inhibited 143B cell migration, invasion and VM formation at noncytotoxic concentrations through decreasing the expression of FAK, Mig-7, MMP2 and MMP9. Finally, daily oral administration of PPEE for four weeks exhibits potent antitumor and anti-VM activity in 143B xenograft model with low toxicity. Taken together, these findings demonstrated PPEE possesses anti-osteosarcoma and anti-VM activity in vitro and in vivo, and therefore is a potential candidate for osteosarcoma treatment.

Objective: To study the chemical constituents from the EtOAc extract of endophytic fungal Plectosphaerella cucumerina YCTA2Z1. Methods: The chemical constituents were isolated and purified by silica gel column, Sephadex LH-20, and reverse-phase C-18 column chromatography as well as crystallization. Results: Thirteen compounds were isolated from the EtOAc extract of the fungal strain YCTA2Z1. Their chemical structures were elucidated according to the spectral evidence. They were identified as caudatin (1), baishouwubenzophenone (2), cynandione B (3), asterbatanoside A (4), p-hydroxyphenethyl-O-beta-D-glycoside (5), caffeic acid (6), ferulic acid (7), 2,5-dihydroxyacetophenone (8), protocatechuic acid (9), vanillic acid (10), stearic acid (11), azelaic acid (12), and succinic acid (13). Conclusions: It is the first chemical study on endophytic fungi from Cynanchum auriculatum and all the compounds are obtained from the species, the genus, as well as the family Plectosphaerellaceae for the first time. (c) 2018 Tianjin Press of Chinese Herbal Medicines. Published by Elsevier B.V. All rights reserved.

Objective To investigate whether vasculogenic mimicry( VM) was present in osteosarcoma and its relevance with patients? clinicopathologic features and prognosis. Methods VM was assessed in osteosarcoma by CD34/PAS double?staining of speci?mens from 66 patients. VM channels were verified to be of osteoblastic origin by staining for osteonectin and osteocalcin, and tumors were also immunohistochemically stained for focal adhesion kinase( FAK) and migration inducing gene?7( Mig?7) to determine whether these markers are associated with the occurrence of VM. The relevance of VM with the prognosis was also investigated. Results VM was observed in 15 of the 66 osteosarcoma samples( 22?7%) , and the incidence of VM didn?t differ with respect to patient sex, age, tumor size, tumor site, surgical type or histological response to pre?operative chemotherapy. However, Kaplan?Meier survival analysis determined that the presence of VM and the tumor necrosis rate after pre?operative chemotherapy were associated with both the overall survival( P=0?011 and 0?040, respectively) and metastasis?free survival( P=0?002 and 0?045, respectively) . Furthermore, Cox pro?portional hazards analysis showed that the presence of VM and the histological response to pre?operative chemotherapy were independent indicators for both poor overall survival( P=0?007 and 0?024, respectively) and poor metastasis?free survival( P=0?002 and 0?027, respectively) . The expression level of FAK and Mig?7 were higher in VM group than non?VM group( P=0?017 and 0?021, respective?ly) . Conclusion These results demonstrate the presence of VM in osteosarcoma and suggest that VM is an unfavorable prognostic fac?tor with FAK and Mig?7 expression as a potential associated mechanism of VM formation in osteosarcoma.

The aim of this study was to investigate the antitumor and antivascular effects of PD806, a new oral prodrug of AVE8063 in vitro and in vivo. The cytotoxicity of PD806 was determined against H22, Walker 256, A549, MCF-7, and BEL-7402 cells using MTT assays. Plasma pharmacokinetic analysis of AVE8063 generated in rats after a single oral administration of PD806 was carried out using the high-performance liquid chromatography method. H22 tumor-bearing mice models were used to show the antitumor activity. Antivascular responses were monitored by in vivo MRI and immunohistochemistry (CD31) in W256 tumor-bearing rats. A blood test and histopathology were performed to evaluate the toxicity of PD806. PD806 showed cytotoxicity against five types of tumor cell lines with the IC50 values in the micromolar concentration. A pharmacokinetic study indicated that PD806 converted into the active form, AVE8063, which showed a half-life of 5.24±0.70 h in rats. Daily oral administration of PD806 inhibited the growth of subcutaneously implanted H22 tumors in a dose-dependent manner. The tumor volume in the 300 mg/kg PD806 group was obviously smaller than that of the vehicle control group from day 6 onward (P<0.05), with inhibition rates of 62% on day 30. PD806 in the three-dose group significantly prolonged the survival of the H22 tumor-bearing mice (P<0.05). At 24 h after PD806 (150 and 200 mg/kg) was administered orally, tumor vascular shutdown was found on CE-T1WI with the presence of extended necrosis and tumor residue at the periphery. The enhancement ratio decreased significantly from 1.00±0.00 at baseline to 0.26±0.08 and 0.17±0.06, respectively (P<0.01). The necrosis ratio measured from CE-T1WI increased significantly from 34% in average at baseline to 52.96 and 60.30%, respectively (P<0.05). Immunohistochemical staining of tumor sections showed a marked reduction in CD31 staining vessels, with microvessel density reduced significantly to 8.71±1.76 and 3.33±1.04, respectively, compared with the vehicle control group (P<0.01). The results of hematology and histopathology showed that PD806 exerted no obvious toxicity during the treatment period. In conclusion, our results indicate that PD806 is an effective and safe vascular disrupting agent.

The purpose of this study was to investigate the effect of combretastatin A4 phosphate (CA4P) on vasculogenic mimicry (VM) channel formation in vitro and in vivo after a single-dose treatment and the underlying mechanism involved in supporting VM. In vitro model of three-dimensional cultures was used to test the effect of CA4P on the tube formation of Walker 256 cells. Western blot analysis was conducted to assess the expression of hypoxia-inducible factor (HIF)-1α and VM-associated markers. W256 tumor-bearing rat model was established to demonstrate the effect of CA4P on VM formation and tumor hypoxia by double staining and a hypoxic marker pimonidazole. Anti-tumor efficacy of CA4P treatment was evaluated by tumor growth curve. Under hypoxic conditions for 48 h in vitro, W256 cells formed VM network associated with increased expression of VM markers. Pretreatment with CA4P did not influence the amount of VM in 3-D culture as well as the expression of these key molecules. In vivo, W256 tumors showed marked intratumoral hypoxia after CA4P treatment, accompanied by increased VM formation. CA4P exhibited only a delay in tumor growth within 2 days but rapid tumor regrowth afterward. VM density was positively related to tumor volume and tumor weight at day 8. CA4P causes hypoxia which induces VM formation in W256 tumors through HIF-1α/EphA2/PI3K/matrix metalloproteinase (MMP) signaling pathway, resulting in the consequent regrowth of the damaged tumor.

Focal adhesion kinase (FAK) has been implicated in tumorigenesis in various malignancies. We sought to examine the expression patterns of FAK and the activated form, phosphorylated FAK (pFAK), in human osteosarcoma and to investigate the correlation of FAK expression with clinicopathologic parameters and prognosis. In addition, the functional consequence of manipulating the FAK protein level was investigated in human osteosarcoma cell lines. Immunohistochemical staining was used to detect FAK and pFAK in pathologic archived materials from 113 patients with primary osteosarcoma. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognoses. The role of FAK in the cytological behavior of MG63 and 143B human osteosarcoma cell lines was studied via FAK protein knock down with siRNA. Cell proliferation, migration, invasiveness and apoptosis were assessed using the CCK8, Transwell and Annexin V/PI staining methods. Both FAK and pFAK were overexpressed in osteosarcoma. There were significant differences in overall survival between the FAK-/pFAK- and FAK+/pFAK- groups (P = 0.016), the FAK+/pFAK- and FAK+/pFAK+ groups (P = 0.012) and the FAK-/pFAK- and FAK+/pFAK+ groups (P < 0.001). There were similar differences in metastasis-free survival between groups. The Cox proportional hazards analysis showed that the FAK expression profile was an independent indicator of both overall and metastasis-free survival. SiRNA-based knockdown of FAK not only dramatically reduced the migration and invasion of MG63 and 143B cells, but also had a distinct effect on osteosarcoma cell proliferation and apoptosis. These results collectively suggest that FAK overexpression and phosphorylation might predict more aggressive biologic behavior in osteosarcoma and may be an independent predictor of poor prognosis.